Adam Pluzanski
Overview
Explore the profile of Adam Pluzanski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
7796
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Pluzanski A, Bryl M, Chmielewska I, Czyzewicz G, Luboch-Kowal J, Wrona A, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900371
Non-small-cell lung cancer (NSCLC) represents 85% of new cases of lung cancer. Over the past two decades, treatment of patients with NSCLC has evolved from the empiric use of chemotherapy...
12.
Zaborowska-Szmit M, Szmit S, Olszyna-Serementa M, Badurak P, Zajda K, Janowicz-Zebrowska A, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831618
The study was conducted in the era when maintenance immunotherapy with durvalumab was not available in clinical practice after chemoradiotherapy (CRT) in unresectable non-small-cell lung cancer (NSCLC). The main aim...
13.
Knetki-Wroblewska M, Tabor S, Pluzanski A, Lewandowska Z, Tysarowski A, Pawlik H, et al.
Curr Oncol
. 2023 Jan;
30(1):462-475.
PMID: 36661686
Background The implementation of next-generation sequencing (NGS) into daily practice allows for the identification of a greater number of molecular abnormalities. We aimed to confirm the benefits of immunotherapy in...
14.
Kucharczyk T, Krawczyk P, Kowalski D, Pluzanski A, Kubiatowski T, Kalinka E
Cancers (Basel)
. 2022 Nov;
14(21).
PMID: 36358717
Mutations and fusions of (rearranged during transfection) gene are detected in a few common types of tumors including thyroid or non-small cells lung cancers. Multiple kinase inhibitors (MKIs) do not...
15.
Brahmer J, Lee J, Ciuleanu T, Bernabe Caro R, Nishio M, Urban L, et al.
J Clin Oncol
. 2022 Oct;
41(6):1200-1212.
PMID: 36223558
Purpose: We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic non-small-cell lung cancer, regardless of...
16.
Paz-Ares L, Ciuleanu T, Pluzanski A, Lee J, Gainor J, Otterson G, et al.
J Thorac Oncol
. 2022 Sep;
18(1):79-92.
PMID: 36049658
Introduction: We characterized the safety of first-line nivolumab plus ipilimumab (NIVO+IPI) in a large patient population with metastatic NSCLC and efficacy outcomes after NIVO+IPI discontinuation owing to treatment-related adverse events...
17.
Janzic U, Turnsek N, Dediu M, Donev I, Lupu R, Teodorescu G, et al.
Curr Oncol
. 2022 Aug;
29(8):5833-5845.
PMID: 36005198
The targeted therapy with tyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor mutation (EGFRm) in advanced non-small cell lung cancer (NSCLC) changed the treatment paradigm. REFLECT study (NCT04031898)...
18.
Piorek A, Pluzanski A, Teterycz P, Kowalski D, Krzakowski M
Cancers (Basel)
. 2022 Apr;
14(7).
PMID: 35406437
Due to the low incidence of primary tracheal neoplasms, there is no uniform system for staging of this disease. Our retrospective analysis based on registry data included 89 patients diagnosed...
19.
Agbarya A, Shalata W, Addeo A, Charpidou A, Cuppens K, Brustugun O, et al.
J Clin Med
. 2022 Mar;
11(6).
PMID: 35330063
Daily-practice challenges in oncology have been intensified by the approval of immune checkpoint inhibitors (ICI). We aimed to outline current therapy policies and management of locally advanced unresectable stage III...
20.
Aapro M, Caprariu Z, Chilingirov P, Chrapava M, Curca R, Gales L, et al.
Eur J Cancer
. 2022 Mar;
166:126-133.
PMID: 35290913
Background: Evidence-based antiemetic guidelines offer predominantly consistent recommendations for chemotherapy-induced nausea and vomiting (CINV) prophylaxis. However, studies suggest that adherence to these recommendations is suboptimal. We explored inconsistencies between clinical...